AbCellera Results Presentation Deck

2020 BUSINESS UPDATE. COVID-19 PROGRAM ~400K PATIENTS TREATED WITH BAMLANIVIMAB Bamlanivimab has been evaluated both alone and together with other antibodies in 5,000+ patients across multiple clinical trials. Bamlanivimab alone has been shown to: YLO52IPAMOO NDC 0002-7910-01 bamlanivimab injection 700 mg/20 mL (35 mg/mL) For Must dilute before use Die Single-Dose Val Unused Portion For use under l Use Authorization (Lilly rization (EUA) NDC 0002-7910-01 bamlanivimab injection 700 mg/20 mL (35 mg/mL) For Intravenous Infusion Only Must dilute before use Single-Dose Vial: Discard Unused Portion For use under Emergency Use Authorization (EUA). Lilly Lidde mong 20999கிர telligen d kde Bu Reduce hospitalizations by 70% to 80% in patients recently diagnosed with mild to moderate COVID-19 Ab Cellera Prevent COVID-19 in nursing homes, reducing the risk of contracting COVID-19 by up to 80% Prevent COVID-19-related deaths

View entire presentation